Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 206 results
Filters: Author is Asmuth, David M  [Clear All Filters]
Found 206 results.

Adult

Grant PM, Komarow L, Sanchez A, et al. "Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164." HIV Clin Trials. 2014;15(4):133-9.
Tenforde MW, Gupte N, Dowdy DW, et al. "C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings." PLoS ONE. 2015;10(2):e0117424.
Robbins GK, Spritzler JG, Chan ES, et al. "Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384." Clin. Infect. Dis.. 2009;48(3):350-61.
Grant PM, Komarow L, Lederman MM, et al. "Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164." J. Infect. Dis.. 2012;206(11):1715-23.
Asmuth DM, Murphy RL, Rosenkranz SL, et al. "Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial." J. Infect. Dis.. 2010;201(11):1686-96.
Skowron G, Spritzler JG, Weidler J, et al. "Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects." J. Acquir. Immune Defic. Syndr.. 2009;50(3):250-8.
Gandhi RT, Spritzler J, Chan E, et al. "Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384." J. Acquir. Immune Defic. Syndr.. 2006;42(4):426-34.
Balagopal A, Asmuth DM, Yang W-T, et al. "Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study." J. Acquir. Immune Defic. Syndr.. 2015;70(2):163-71.
Sereti I, Dunham RM, Spritzler J, et al. "IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection." Blood. 2009;113(25):6304-14.

Anti-HIV Agents

Rodriguez B, Asmuth DM, Matining RM, et al. "Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial." J. Acquir. Immune Defic. Syndr.. 2013;64(4):351-9.
Grant PM, Komarow L, Lederman MM, et al. "Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164." J. Infect. Dis.. 2012;206(11):1715-23.
Gandhi RT, Spritzler J, Chan E, et al. "Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384." J. Acquir. Immune Defic. Syndr.. 2006;42(4):426-34.
Balagopal A, Asmuth DM, Yang W-T, et al. "Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study." J. Acquir. Immune Defic. Syndr.. 2015;70(2):163-71.
Asmuth DM, Murphy RL, Rosenkranz SL, et al. "Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial." J. Infect. Dis.. 2010;201(11):1686-96.
George V, Harrison L, Roach M, et al. "Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome." J. Infect. Dis.. 2017;216(9):1159-1163.

Pages